))
Episode 56 - TWITTER SPAC’S CHIP SHORTAGE PHARMA STOCKS
Arkivert serier ("Inaktiv feed" status)
When?
This feed was archived on February 22, 2024 08:11 (
Why? Inaktiv feed status. Våre servere kunne ikke hente en gyldig podcast feed for en vedvarende periode.
What now? You might be able to find a more up-to-date version using the search function. This series will no longer be checked for updates. If you believe this to be in error, please check if the publisher's feed link below is valid and contact support to request the feed be restored or if you have any other concerns about this.
Manage episode 290973560 series 2818443
Innhold levert av Gavin Graham. Alt podcastinnhold, inkludert episoder, grafikk og podcastbeskrivelser, lastes opp og leveres direkte av Gavin Graham eller deres podcastplattformpartner. Hvis du tror at noen bruker det opphavsrettsbeskyttede verket ditt uten din tillatelse, kan du følge prosessen skissert her https://no.player.fm/legal.
Correspondent Samuel Okocha analyses the present and potential future of Twitter Inc.
From London James Athey at Aberdeen Standard Investments questions whether SPACs can continue at their current level.
From San Diego California Peter Merrick of MerrickWealth.com looks at the winners (Taiwan Semiconductor, Intel) and losers (Ford, General Motors, Toyota and Volkswagen) in the current chip shortage.
Gavin Graham dissects the pharmaceutical stock sector and the impact of vaccine news, looking at Pfizer, Johnson & Johnson, AstraZeneca, Moderna and other pharma companies.
89 episoder
Del
